Good afternoon :)
Switch to
Place Order

Nectar Life sciences Ltd

NECLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹653 cr, stock is ranked 1,090
High RiskStock is 4.02x as volatile as Nifty
28.900.25 (-0.86%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹653 cr, stock is ranked 1,090
High RiskStock is 4.02x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
-8.92
PB RatioPB Ratio
0.62
Dividend YieldDiv. Yield
Sector PESector PE
40.27
Sector PBSector PB
5.39
Sector Div YldSctr Div Yld
0.64%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

20182019202020211.882.792.371.550.050.050.03-0.07
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Shareholders meeting 
Announced OnSep 21, 2021

NECLIFE: Nectar Lifesciences Limited has submitted the Exchange a copy Scrutinizers report and outcome of Annual General Meeting held on September 21, 2021. (Searchable Format) | Download

NECLIFE: Nectar Lifesciences Limited has submitted the Exchange a copy Scrutinizers report and outcome of Annual General Meeting held on September 21, 2021. (Searchable Format) | Download

Shareholders meeting 
Announced OnSep 21, 2021

Nectar Lifesciences Limited has submitted the Exchange a copy Scrutinizers report and outcome of Annual General Meeting held on September 21, 2021. | Download

Nectar Lifesciences Limited has submitted the Exchange a copy Scrutinizers report and outcome of Annual General Meeting held on September 21, 2021. | Download

Cash Dividend 
Ex. DateSep 11, 2020

Final • Div/Share: ₹ 0.05

See all events